Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 82.3% from a year ago

Cash & equivalents stood at $13.2M at the end of Q1 FY2026, down 82.3% from a year earlier and down 71.3% from the prior quarter. Over 3 fiscal years it compounded at +4.3% a year.

Context

  • Cash & equivalents amounted to 4.9% of total assets at the end of Q1 FY2026, down 45.6 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -82.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.2M-71.3% QoQ
Last fiscal yearDec 2025
$45.95M-15.6% YoY
Year agoMar 2025
$74.52M-82.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-82.3%——
1 year-15.6%——
3-year CAGR+4.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
45.95M USD
Year-over-year change
-15.6%
4-year CAGR
-12.2%

Cash & Equivalents vs competitors

How ORMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -82.3% is the lowest of 11, against a peer median of -39.3%.
  • Cash & equivalents amounts to 4.9% of total assets for ORMP, versus a peer median of 48.7%.
ORMP Competitors
Cash & Equivalents for ORMP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OVIDOvid Therapeutics Inc.Mar 2026$94.06M USD+345.0%-33.6%41.7%
STTKShattuck Labs, Inc.Mar 2026$90.42M USD+48.5%+4.6%88.5%
IMAImageneBio IncMar 2026$76.05M USD+106.9%-16.4%55.6%
MGNXMacroGenics, Inc.Mar 2026$66.52M USD-54.3%-19.3%30.5%
CNTXContext Therapeutics Inc.Mar 2026$54.53M USD-39.0%+23.0%92.6%
COYACoya Therapeutics, Inc.Mar 2026$50.72M USD+42.8%+99.1%95.2%
CNTBConnect Biopharma Holdings LimitedDec 2025$38.35M USD-51.0%-21.4%68.4%
KLRSKalaris Therapeutics IncMar 2026$34.43M USD-65.9%+217.7%31.4%
IFRXInflaRx N.V.Mar 2026€15.01M EUR-68.3%-0.5%30.7%
ORMPOramed Pharmaceuticals Inc.Mar 2026$13.2M USD-82.3%+4.3%4.9%
CLNNClene Inc.Mar 2026$5.94M USD-39.6%-34.3%27.4%
Peer median (excluding ORMP) —-39.3%-8.5%48.7%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents77.25M40.46M9.06M54.42M45.95M
Short-term Investments16.9M115.26M152.99M87.51M79.95M
Net Receivables00004.64M
Inventory00000
Other Current Assets1.2M1.39M537K1.29M2.74M
Total Current Assets95.34M157.11M162.58M143.22M133.27M
Property, Plant & Equipment (Net)932K1.81M1.57M1.11M1.34M
Goodwill00000
Intangible Assets00000
Long-term Investments6.69M2.7M56.37M10.91M93.74M
Tax Assets00000
Other Non-current Assets25.04M24K34K34K2.52M
Total Non-current Assets32.66M4.53M57.97M12.06M97.59M
Total Assets128M161.64M220.55M155.28M230.86M
Account Payables2.61M2.18M551K789K443K
Short-term Debt130K247K51.01M00
Tax Payables0003.2M0
Deferred Revenue2.7M1.34M001.35M
Other Current Liabilities(1.37M)(191K)325K1.07M2.37M
Total Current Liabilities6.68M5.75M53.21M5.69M19.09M
Long-term Debt403K647K000
Deferred Tax Liabilities11K11K007.91M
Deferred Revenue (Non-current)4.24M4M4M4M3.27M
Other Non-current Liabilities145K82K102K90K314K
Total Non-current Liabilities4.8M4.74M4.44M4.25M12.03M
Total Liabilities11.48M10.49M57.66M9.93M31.12M
Common Stock424K476K485K480K472K
Retained Earnings(114.85M)(163.08M)(157.56M)(176.62M)(123.44M)
Accumulated OCI00000
Other Stockholders Equity230.2M314.42M000
Minority Interest744K(656K)(928K)(918K)0
Total Equity116.52M151.16M162.89M145.35M199.74M
Total Debt533K894K51.62M372K825K
Net Debt(76.71M)(39.57M)42.57M(54.05M)(45.12M)

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.